Navigation Links
Evotec Reports Third Quarter 2007 Results
Date:11/13/2007

/p>

The Group operating result for the first nine months of 2007 amounted to EUR (36.7) million (2006: EUR (25.0) million). The decline is a result of the reduced revenue and gross profit levels, high investment in the advancement and enhancement of Evotec's proprietary pipeline (R&D expenses: +22%) and a related 19% increase in SG&A expenses, including transaction costs for divestments and acquisitions. For the first nine months of 2007, net loss remained on last year's level at EUR 23.6 million (2006: EUR 24.6 million). This is due to a non-operating profit from the divestment of Evotec Technologies GmbH to PerkinElmer (EUR 11.2 million), the divestment of shares of Direvo Biotech AG (EUR 0.5 million) and high interest income due to increased cash levels (EUR 1.0 million).

In total, cash and cash equivalents at the end of September 2007 on a proforma basis including proceeds from the divestment of Evotec's Chemical Development Business to Aptuit, Inc. (approximately EUR 46.4 million) amounted to EUR 106.8 million. The reported cash position excluding the proceeds from the divestment to Aptuit was EUR 60.4 million (December 31, 2006: EUR 78.1 million). The decrease mainly results from high R&D investment and an increase in working capital by EUR 10.6 million compared to the extraordinarily low level of working capital recorded at year-end 2006.

Corporate Events:

- Compelling proof-of-concept data achieved in two Phase II studies with insomnia drug candidate EVT 201

- In adult insomniacs (first study), EVT 201 showed highly statistically significant effects on sleep onset and maintenance and was free of any subjective evidence of hang-over, thereby revealing a competitive drug profile

- Top-line results of the second study in elderly insomniacs confirmed the robust effects seen in the first study and indicate that the same doses show hypnotic efficacy in the elderly as well as positive effects on day-time performance (less sleepiness)
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that ... from 17 different countries will converge on the ... Valley for an intensive, experiential program focused on ... The highly selective school, currently running its sixth ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... of molecular diagnostic test results. It also enables ... for the validation and reporting of high profile ... diagnostics is a rapidly growing area of biotechnology ... genetic predisposition, cancer, and companion diagnostics in personalized ...
(Date:7/23/2014)... strides in saving China,s endangered national treasure, the giant ... panda reserves that have been established and three large ... remain in the wild. , Breeding programs in ... by improving genetic diversity, avoid inbreeding and ultimately, introduce ... high-profile programs doing so far? , In a new ...
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2
... and development will dominate a surge in demand for ... study released this week by a New York consulting ... Lux Research , also projected that sales of ... years. , ,"Interest in nanotechnology focuses on remarkable applications ...
... Fiserv, Inc. and CUNA Mutual Group ... of CUNA Mutual's payment protection products during ... solutions offered by Fiserv business units. The ... protection products, which include credit life, credit disability and ...
... Source: Visions 2005 Madison, Wis. - ... of postage stamp size videos of staid corporate meetings, running ... of the seafloor? , ,Audiences will have the opportunity to ... The Sea" event, hosted locally by the UW-Madison Division ...
Cached Biology Technology:Corporate clients will dominate surge in nanotech tool demand, study projects 2Corporate clients will dominate surge in nanotech tool demand, study projects 3Deep sea event will put spotlight on Internet 2 capabilities 2
(Date:7/24/2014)... sake brewery has its own microbial terroir, meaning the ... those found in the product, creating the final flavor ... journal Applied and Environmental Microbiology . This is ... of a sake brewery. , Many sake makers ... David A. Mills of the University of California, Davis, ...
(Date:7/24/2014)... similar counterparts in humans, affect the connections between nerve ... the hippocampus, an area of the brain that plays ... of memories. The results of the study have been ... function depends on the active communication between nerve cells, ... together into a dense network where they constantly relay ...
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... HOBOKEN, N.J. Stevens Institute of Technology,s Center for ... Warning System (EWS) for Inundations in the Dominican Republic. ... DR,s EWS and providing the most up-to-date equipment to ... on the island. , The genesis of the EWS ...
... Wistar Institute and their colleagues have identified, for the first ... of RNA that play a vital role in gene expression ... way to the development of a new generation of cancer ... that blocks the pathway of a particular miRNA, called miR-21, ...
... September 23, 2008 Researchers at Sentara ... explore the safety and effectiveness of stents to open ... Pulmonary Disease (COPD). The EASE (Exhale Airway ... investigational technique without surgery to create new pathways to ...
Cached Biology News:Stevens strengthens Dominican Republic's Early Warning System for Inundations 2Stevens strengthens Dominican Republic's Early Warning System for Inundations 3Scientists identify novel inhibitor of human microRNA 2Scientists identify novel inhibitor of human microRNA 3Sentara begins international trial -- open at only 24 US locations 2
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: